HRP20210981T1 - Imidazolonyl quinolines and their use as atm kinase inhibitors - Google Patents

Imidazolonyl quinolines and their use as atm kinase inhibitors Download PDF

Info

Publication number
HRP20210981T1
HRP20210981T1 HRP20210981TT HRP20210981T HRP20210981T1 HR P20210981 T1 HRP20210981 T1 HR P20210981T1 HR P20210981T T HRP20210981T T HR P20210981TT HR P20210981 T HRP20210981 T HR P20210981T HR P20210981 T1 HRP20210981 T1 HR P20210981T1
Authority
HR
Croatia
Prior art keywords
pyrazol
methyl
tautomer
stereoisomer
solvate
Prior art date
Application number
HRP20210981TT
Other languages
Croatian (hr)
Inventor
Thomas Fuchss
Kai Schiemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20210981T1 publication Critical patent/HRP20210981T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (14)

1. Spoj s formulom (I) [image] naznačen time što R1 je metil, R3 označava nerazgranat ili razgranat alkil koji ima 1, 2 ili 3 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4 ili 5 H atoma mogu biti zamijenjeni s Hal, Het1 je odabran iz niza koji čine pirazolil, triazolil i imidazolil, pri čemu Het1 može biti nesupstituiran ili mono- ili disupstituiran, neovisno jedan od drugoga, s alkilom, koji može biti nesupstituiran ili mono- ili polisupstituiran s Hal, -OY, -NYY, Hal i -Het2, HET označava 5-eročlani monociklički aromatski heterocikl, gdje je ovaj heterocikl povezan s N atomom kostura preko prstenskog C atoma i gdje je ovaj heterocikl odabran od pirazolila, tiazolila i imidazolila i može biti nesupstituiran ili supstituiran s jednim, dva ili tri supstituenta, koji su odabrani, neovisno jedan od drugoga, iz skupine koja sadrži: Hal, A, Het2, -(CY2)p-OY, -(CY2)p-OZ, -(CY2)p-O-Het2, -(CY2)p-O-(CY2)t-Het2, -(CY2)p-O-(CY2)t-NYY, -(CY2)p-O-(CY2)t-OY, -(CY2)p-NYY, -(CY2)p-COOY, -(CY2)p-CO-NYY, -(CY2)p-NY-COY, A svaki puta neovisno označava nerazgranat ili razgranat alkil koji ima 1, 2, 3, 4, 5, 6, 7, 8, 9 ili 10 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4, 5, 6 ili 7 H atoma mogu biti zamijenjeni s Hal, Het2 označava monociklički zasićeni heterocikl koji ima 2, 3, 4, 5, 6 ili 7 C atoma i 1, 2, 3 ili 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili monosupstituirani s A, Y označava H ili A, Z označava nerazgranat ili razgranat alkenil koji ima 2, 3, 4, 5, 6, 7, 8, 9 ili 10 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4, 5, 6 ili 7 H atoma mogu biti zamijenjeni s Hal, Hal označava F, Cl, Br ili I, i p označava 0, 1, 2, 3, 4, 5 ili 6 t označava 1, 2, 3, 4, 5 ili 6, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.1. Compound with formula (I) [image] indicated by what R1 is methyl, R3 denotes unbranched or branched alkyl having 1, 2 or 3 C atoms, where, independently of each other, 1, 2, 3, 4 or 5 H atoms can be replaced by Hal, Het1 is selected from the group consisting of pyrazolyl, triazolyl and imidazolyl, whereby Het1 can be unsubstituted or mono- or disubstituted, independently of each other, with alkyl, which can be unsubstituted or mono- or polysubstituted with Hal, -OY, -NYY , Hal and -Het2, HET denotes a 5-membered monocyclic aromatic heterocycle, where this heterocycle is connected to the N atom of the skeleton through a ring C atom and where this heterocycle is selected from pyrazolyl, thiazolyl and imidazolyl and may be unsubstituted or substituted with one, two or three substituents, which are selected independently from the group consisting of: Hal, A, Het2, -(CY2)p-OY, -(CY2)p-OZ, -(CY2)p-O-Het2, -(CY2)p-O-(CY2 )t-Het2, -(CY2)p-O-(CY2)t-NYY, -(CY2)p-O-(CY2)t-OY, -(CY2)p-NYY, -(CY2)p-COOY, -(CY2 )p-CO-NYY, -(CY2)p-NY-COY, And each time independently denotes straight or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, where, independently of each other, 1, 2, 3, 4, 5, 6 or 7 H atoms can be replaced by Hal, Het2 denotes a monocyclic saturated heterocycle having 2, 3, 4, 5, 6 or 7 C atoms and 1, 2, 3 or 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted with A, Y stands for H or A, Z represents unbranched or branched alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, where, independently of each other, 1, 2, 3, 4, 5, 6 or 7 H atoms can be replaced with Hal, Hal stands for F, Cl, Br or I, and p stands for 0, 1, 2, 3, 4, 5 or 6 t stands for 1, 2, 3, 4, 5 or 6, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof. 2. Spoj s formulom (I) prema patentnom zahtjevu 1, naznačen time što HET može biti supstituiran s jednim, dva ili tri supstituenta koji su odabrani, neovisno jedan od drugoga, iz skupine koja sadrži: F, Cl, metil, etil, propil, izopropil, metoksi, etoksi, propoksi, piperazinil, tetrahidropiranil, 2-metoksietoksi, 2-hidroksietoksi, fluorometoksi, difluorometoksi, N-metilkarbamoil (-C(=O)-NH-CH3), 2-metilaminoetoksi, 1-metil-azetidin-3-ilmetoksi, trideuteriometoksi, trifluorometoksi, aliloksi i azetidiniloksi, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.2. Compound with formula (I) according to patent claim 1, characterized in that HET can be substituted with one, two or three substituents that are selected, independently of each other, from the group containing: F, Cl, methyl, ethyl, propyl , isopropyl, methoxy, ethoxy, propoxy, piperazinyl, tetrahydropyranyl, 2-methoxyethoxy, 2-hydroxyethoxy, fluoromethoxy, difluoromethoxy, N-methylcarbamoyl (-C(=O)-NH-CH3), 2-methylaminoethoxy, 1-methyl-azetidine -3-ylmethoxy, trideuteriomethoxy, trifluoromethoxy, allyloxy and azetidinyloxy, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof. 3. Spoj s formulom (I) prema patentnom zahtjevu 1 ili 2, naznačen time što je HET odabran iz skupa koji čine: 1H-pirazol-4-il, 1-etil-3-metil-1H-pirazol-4-il, 1,2-dimetil-1H-pirazol-4-il, 1,3-dimetil-1H-pirazol-4-il, 1-metil-1 H-pirazol-4-il, 1-(tetrahidropiran-4-il)-1H-pirazol-4-il, 2-metil-2H-pirazol-3-il, 3-metil-1H-pirazol-4-il, 2-metilol-4-il, 3,5-dimetil-1H-pirazol-4-il, 3-fluoro-1-metilpirazol-4-il, tiazol-2-il, i 1-metil-1H-imidazolil, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.3. Compound with formula (I) according to claim 1 or 2, characterized in that HET is selected from the group consisting of: 1H-pyrazol-4-yl, 1-ethyl-3-methyl-1H-pyrazol-4-yl, 1,2-dimethyl-1H-pyrazol-4-yl, 1,3-dimethyl-1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl, 1-(tetrahydropyran-4-yl) -1H-pyrazol-4-yl, 2-methyl-2H-pyrazol-3-yl, 3-methyl-1H-pyrazol-4-yl, 2-methylol-4-yl, 3,5-dimethyl-1H-pyrazole -4-yl, 3-fluoro-1-methylpyrazol-4-yl, thiazol-2-yl, and 1-methyl-1H-imidazolyl, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof. 4. Spoj s formulom (I) prema patentnom zahtjevu 1, 2 ili 3, naznačen time što Het1 je pirazolil, koji može biti nesupstituiran ili supstituiran kako je definirano u patentnom zahtjevu 1, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.4. Compound with formula (I) according to claim 1, 2 or 3, characterized in that Het1 is pyrazolyl, which can be unsubstituted or substituted as defined in claim 1, and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer. 5. Spoj s formulom (I) prema patentnom zahtjevu 1, 2 ili 3, naznačen time što Het1 je triazolil, poželjno 1,2,3-triazolil, koji može biti nesupstituiran ili supstituiran kako je definirano u patentnom zahtjevu 1, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.5. Compound with formula (I) according to claim 1, 2 or 3, characterized in that Het1 is triazolyl, preferably 1,2,3-triazolyl, which can be unsubstituted or substituted as defined in claim 1, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof. 6. Spoj s formulom (I) prema jednom od patentnih zahtjeva 1 do 4, naznačen time što Het1 je nesupstituiran ili supstituiran s jednim ili dva supstituenta odabrana, neovisno jedan od drugoga, od metila, etila, amino, metoksi, fluorometila, difluorometila, fluora, azetidinila, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.6. Compound with formula (I) according to one of claims 1 to 4, characterized in that Het1 is unsubstituted or substituted with one or two substituents selected, independently of each other, from methyl, ethyl, amino, methoxy, fluoromethyl, difluoromethyl, fluoro, azetidinyl, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof. 7. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je Het1 naznačen time što je odabran iz skupa koji čine: 1H-pirazol-4-il, 2H-pirazol-3-il, 1H-pirazol-3-il, 1-metil-1H-pirazol-4-il, 3-metil-1H-pirazol-4-il, 5-metil-1H-pirazol-3-il, 4-metil-1H-pirazol-3-il, 1-fluorometil-1H-pirazol-4-il, 1-difluorometil-1H-pirazol-4-il, 1,3-dimetil-1H-pirazol-4-il, 1-etil-1H-pirazol-4-il, 1-etil-3-metil-1H-pirazolil, 3-fluoro-1-metil-1H-pirazol-4-il, 3-amino-1H-pirazol-5-il, 2H-1,2,3-triazol-4-il, 3H-1,2,3-triazol-4-il-, 1-metil-1H-1,2,3-triazol-4-il, 2-metil-2H-1,2,3-triazol-4-il, 2-amino-1H-imidazol-4-il, i 1-(azetidin-3-il)-3-metil-1H-pirazol-4-il, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.7. Compound with formula (I) according to any one of claims 1 to 4, characterized in that Het1 is selected from the group consisting of: 1H-pyrazol-4-yl, 2H-pyrazol-3-yl, 1H -pyrazol-3-yl, 1-methyl-1H-pyrazol-4-yl, 3-methyl-1H-pyrazol-4-yl, 5-methyl-1H-pyrazol-3-yl, 4-methyl-1H-pyrazole -3-yl, 1-fluoromethyl-1H-pyrazol-4-yl, 1-difluoromethyl-1H-pyrazol-4-yl, 1,3-dimethyl-1H-pyrazol-4-yl, 1-ethyl-1H-pyrazole -4-yl, 1-ethyl-3-methyl-1H-pyrazolyl, 3-fluoro-1-methyl-1H-pyrazol-4-yl, 3-amino-1H-pyrazol-5-yl, 2H-1,2 ,3-triazol-4-yl, 3H-1,2,3-triazol-4-yl-, 1-methyl-1H-1,2,3-triazol-4-yl, 2-methyl-2H-1, 2,3-triazol-4-yl, 2-amino-1H-imidazol-4-yl, and 1-(azetidin-3-yl)-3-methyl-1H-pyrazol-4-yl, and/or its pharmaceutical useful salt, solvate, tautomer or stereoisomer. 8. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što R3 označava metil, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.8. Compound with formula (I) according to any one of patent claims 1 to 7, characterized in that R 3 denotes methyl, and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer. 9. Spoj prema patentnom zahtjevu 1, naznačen time što je odabran iz skupa koji čine: [image] [image] [image] [image] i/ili njihova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.9. Compound according to patent claim 1, characterized in that it is selected from the group consisting of: [image] [image] [image] [image] and/or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof. 10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu kao lijek.10. A compound according to any one of claims 1 to 9 and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer, characterized in that it is for use as a medicine. 11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza, po izboru u kombinaciji s radioterapijom ili najmanje jednim sredstvom protiv raka.11. A compound according to any one of claims 1 to 9 and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer, characterized in that it is for use in the treatment of cancer, tumors and/or metastases, optionally in combination with radiotherapy or at least one anti-cancer agent. 12. Spoj prema jednom od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u senzibilizaciji stanica karcinoma na sredstvo protiv raka i/ili ionizirajuće zračenje.12. A compound according to one of claims 1 to 9 and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer, characterized in that it is for use in sensitization of cancer cells to an anticancer agent and/or ionizing radiation. 13. Farmaceutski pripravak naznačen time što sadrži učinkovitu količinu najmanje jednog spoja prema jednom od patentnih zahtjeva 1 do 9 i/ili njegovu farmaceutski upotrebljivu sol, solvat, tautomer ili stereoizomer, po izboru zajedno s najmanje jednim farmaceutski podnošljivim pomoćnim sastojkom.13. Pharmaceutical preparation characterized in that it contains an effective amount of at least one compound according to one of claims 1 to 9 and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer, optionally together with at least one pharmaceutically acceptable auxiliary ingredient. 14. Komplet koji se sastoji od zasebnih pakiranja (a) učinkovite količine spoja prema jednom od patentnih zahtjeva 1 do 9 i/ili njegove farmaceutski upotrebljive soli, solvata, tautomera ili stereoizomera, i (b) učinkovite količine sredstva protiv raka.14. A set consisting of separate packages (a) an effective amount of the compound according to one of claims 1 to 9 and/or its pharmaceutically usable salt, solvate, tautomer or stereoisomer, and (b) effective amounts of the anticancer agent.
HRP20210981TT 2015-04-02 2021-06-23 Imidazolonyl quinolines and their use as atm kinase inhibitors HRP20210981T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
EP19172903.7A EP3560924B1 (en) 2015-04-02 2016-03-31 Imidazolonyl quinolines and their use as atm kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20210981T1 true HRP20210981T1 (en) 2021-09-17

Family

ID=52814780

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20191396 HRP20191396T1 (en) 2015-04-02 2019-08-01 Imidazolonyl quinolines and their use as atm kinase inhibitors
HRP20210981TT HRP20210981T1 (en) 2015-04-02 2021-06-23 Imidazolonyl quinolines and their use as atm kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20191396 HRP20191396T1 (en) 2015-04-02 2019-08-01 Imidazolonyl quinolines and their use as atm kinase inhibitors

Country Status (24)

Country Link
US (5) US10457677B2 (en)
EP (3) EP3277681B1 (en)
JP (2) JP6791873B2 (en)
KR (2) KR102652052B1 (en)
CN (3) CN107889488B (en)
AU (3) AU2016239270B2 (en)
BR (1) BR122019005502B1 (en)
CA (1) CA2981365A1 (en)
DK (2) DK3560924T3 (en)
ES (3) ES2880626T3 (en)
HR (2) HRP20191396T1 (en)
HU (2) HUE045477T2 (en)
IL (3) IL254714B (en)
LT (2) LT3560924T (en)
MX (2) MX2020011558A (en)
PL (2) PL3277681T3 (en)
PT (2) PT3560924T (en)
RS (2) RS59139B1 (en)
RU (1) RU2743343C2 (en)
SG (2) SG10202002181UA (en)
SI (2) SI3277681T1 (en)
TR (1) TR201911244T4 (en)
WO (1) WO2016155884A1 (en)
ZA (1) ZA201707423B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880626T3 (en) * 2015-04-02 2021-11-25 Merck Patent Gmbh Imidazolonylquinolines
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2018153365A1 (en) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 Substituted fused heteroaryl tricyclic compound as kinase inhibitor and application thereof
JOP20190209A1 (en) * 2017-03-16 2019-09-12 Astrazeneca Ab Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2019206623A1 (en) 2018-01-12 2020-07-16 Prolynx Llc Synergistic cancer treatment
US20210353614A1 (en) * 2018-03-14 2021-11-18 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
CN111989323A (en) 2018-04-12 2020-11-24 拜耳公司 N- (cyclopropylmethyl) -5- (methylsulfonyl) -N- {1- [1- (pyrimidin-2-yl) -1H-1, 2, 4-triazol-5-yl ] ethyl } benzamide derivatives and corresponding picolinamide derivatives as pesticides
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (en) * 2018-04-20 2019-10-29 艾科思莱德制药公司 For the dual ATM and DNA-PK inhibitor in antitumor therapy
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (en) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Application of the ATM inhibitor in the drug that preparation inhibits acute lymphatic leukemia recurrence
BR112021005989A2 (en) * 2018-09-30 2021-06-29 Medshine Discovery Inc. quinoline-pyrrolidin-2-one derivatives and their application
EP3947375B1 (en) 2019-03-27 2024-04-03 Merck Patent GmbH Imidazolonylquinoline compounds and therapeutic uses thereof
CN114258301A (en) * 2019-07-30 2022-03-29 艾科思莱德制药公司 Dual ATM and DNA-PK inhibitors for use in antitumor therapy
IL292613A (en) 2019-11-01 2022-07-01 Ares Trading Sa Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer
EP4069366A1 (en) 2019-12-04 2022-10-12 CHDI Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
CN115003672A (en) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 Quinoline imidazole compound and application thereof
CN115380031A (en) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 Crystal form of quinoline pyrrolidine-2-ketone compound as ATM inhibitor and application thereof
JP2023530004A (en) * 2020-06-18 2023-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds for the treatment of viral infections
TW202216209A (en) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and atm inhibitor
BR112023002078A2 (en) 2020-09-18 2023-03-28 Merck Patent Gmbh PHARMACEUTICAL PREPARATION
KR20230026478A (en) 2020-09-21 2023-02-24 웨이 중 Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-C]quinolin-2-one compounds with blood-brain barrier penetration ability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN115232122A (en) * 2021-04-23 2022-10-25 石药集团中奇制药技术（石家庄）有限公司 Alkyne compound and preparation and application thereof
CN115716829A (en) * 2022-11-13 2023-02-28 药康众拓(江苏)医药科技有限公司 Quinolinoimidazolidone deuterated pyrazole compound and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DK1879893T3 (en) 2005-03-21 2010-09-13 Ferrer Int Process for the Preparation of 1-Substituted 1H-Imidazo [4,5-c] Quinoline-4-Amine Compounds and Intermediates
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101616672A (en) 2007-02-20 2009-12-30 诺瓦提斯公司 Imidazoquinolines as lipid kinase and mTOR double inhibitor
BRPI0909082A2 (en) 2008-03-26 2019-02-26 Novartis Ag imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-triggered angiogenic processes
PE20140407A1 (en) * 2008-06-10 2014-04-25 Abbott Lab NEW TRICYCLIC COMPOUNDS
MX340304B (en) 2008-10-01 2016-07-05 Novartis Ag * Smoothened antagonism for the treatment of hedgehog pathway-related disorders.
EP2438064A1 (en) * 2009-06-04 2012-04-11 Novartis AG 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EP2438063A1 (en) 2009-06-04 2012-04-11 Novartis AG 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
BR112012022868A2 (en) * 2010-03-16 2018-06-05 Merck Patent Gmbh morpholinylquinazolines
PE20130376A1 (en) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
CN102372711B (en) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 Imidazo quinoline PI3K and mTOR (mammalian target of rapamycin) dual inhibitor
DE102010035744A1 (en) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (en) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 Triheterocyclic compounds and their use as PI3K inhibitors
PE20140792A1 (en) 2010-12-03 2014-07-09 Novartis Ag PHARMACEUTICAL COMPOSITIONS
CN103012398B (en) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 Imidazoquinoline analog derivative and pharmacologically acceptable salt thereof, its preparation method and in application pharmaceutically
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
CN104349771A (en) 2012-06-06 2015-02-11 诺华股份有限公司 Combination of 17[alpha]-hydroxylase (c17, 20-lyase) inhibitor and specific PI-3K inhibitor for treating tumor disease
NO2714752T3 (en) * 2014-05-08 2018-04-21
ES2880626T3 (en) * 2015-04-02 2021-11-25 Merck Patent Gmbh Imidazolonylquinolines

Also Published As

Publication number Publication date
HRP20191396T1 (en) 2019-11-01
IL271494B (en) 2021-05-31
DK3560924T3 (en) 2021-06-28
CN111747952A (en) 2020-10-09
ES2880626T3 (en) 2021-11-25
EP3560924A1 (en) 2019-10-30
CA2981365A1 (en) 2016-10-06
AU2020204241B2 (en) 2022-11-17
TR201911244T4 (en) 2019-08-21
US10975075B2 (en) 2021-04-13
JP7111790B2 (en) 2022-08-02
SI3277681T1 (en) 2019-09-30
JP2021046403A (en) 2021-03-25
EP3868761B1 (en) 2023-03-01
AU2020204241A1 (en) 2020-07-16
EP3277681A1 (en) 2018-02-07
ES2946507T3 (en) 2023-07-20
SI3560924T1 (en) 2021-08-31
BR122019005502B1 (en) 2024-02-27
RU2743343C2 (en) 2021-02-17
AU2022256215A1 (en) 2022-11-24
IL282584B (en) 2021-12-01
BR112017020941A2 (en) 2018-07-10
US20190211013A1 (en) 2019-07-11
LT3560924T (en) 2021-08-25
EP3560924B1 (en) 2021-03-31
US10457677B2 (en) 2019-10-29
DK3277681T3 (en) 2019-07-29
SG10202002181UA (en) 2020-05-28
IL254714A0 (en) 2017-11-30
EP3277681B1 (en) 2019-05-08
HUE054745T2 (en) 2021-09-28
US20230203034A1 (en) 2023-06-29
ES2741853T3 (en) 2020-02-12
EP3868761A1 (en) 2021-08-25
RU2017138100A3 (en) 2019-10-04
IL254714B (en) 2020-01-30
KR102652052B1 (en) 2024-03-27
JP6791873B2 (en) 2020-11-25
MX2020011558A (en) 2022-03-09
RS62082B1 (en) 2021-08-31
US20200325137A1 (en) 2020-10-15
PL3560924T3 (en) 2021-10-11
PT3277681T (en) 2019-08-20
KR20240044525A (en) 2024-04-04
SG11201708065QA (en) 2017-10-30
AU2016239270B2 (en) 2020-03-26
ZA201707423B (en) 2021-05-26
MX2017012613A (en) 2018-01-24
US10745399B2 (en) 2020-08-18
LT3277681T (en) 2019-08-12
PL3277681T3 (en) 2019-10-31
US11608338B2 (en) 2023-03-21
KR20170132323A (en) 2017-12-01
HUE045477T2 (en) 2019-12-30
AU2016239270A1 (en) 2017-11-16
US20210198257A1 (en) 2021-07-01
IL271494A (en) 2020-02-27
WO2016155884A1 (en) 2016-10-06
RU2017138100A (en) 2019-05-08
JP2018510191A (en) 2018-04-12
US20180072715A1 (en) 2018-03-15
CN111689963A (en) 2020-09-22
IL282584A (en) 2021-06-30
PT3560924T (en) 2021-07-02
RS59139B1 (en) 2019-09-30
CN107889488B (en) 2020-08-11
CN107889488A (en) 2018-04-06

Similar Documents

Publication Publication Date Title
HRP20210981T1 (en) Imidazolonyl quinolines and their use as atm kinase inhibitors
HRP20180382T1 (en) Protein kinase inhibitors
Ku et al. Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells
JP2014070075A5 (en)
CU24355B1 (en) DERIVATIVES OF 2 (((OXADIAZOL / TRIAZOL / TETRAZOL / ISOXAZOL) METHYL) PHENYL) -1- (HETEROCICLYL) -ONE AS ACTIVE AUTOTAXIN INHIBITORS
HRP20160421T1 (en) Azole derivative
JP2016535772A5 (en)
HRP20161396T1 (en) 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
GT201700094A (en) HYDROXYALKYL SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND THEIR USES
JP2018510191A5 (en)
JP2017528504A5 (en)
TN2012000347A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
ZA201803747B (en) 4-((6-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
RU2014147381A (en) Pyrazolamine-pyrimidine derivatives as modulators enriched in leucine repeats of kinase 2
JP2015531366A5 (en)
PE20081379A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDED BY NILOTINIB
US20160264564A1 (en) Pyrazol-3-ones That Activate Pro-apoptotic BAX
Wang et al. Design, synthesis and biological evaluation of bromophenol-thiazolylhydrazone hybrids inhibiting the interaction of translation initiation factors eIF4E/eIF4G as multifunctional agents for cancer treatment
Abd-Rabou et al. Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1, 2, 3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents
Zhang et al. Biological activities of novel pyrazolyl hydroxamic acid derivatives against human lung cancer cell line A549
JP2014208663A5 (en)
AR108265A1 (en) FENILTRIAZOL DERIVATIVES REPLACED WITH AMIDA AND USES OF THESE
JP2016520635A5 (en)
JP2015524825A5 (en)
CO2018011948A2 (en) Process for the preparation of 1-phenyl-1,2,4-triazole derivatives substituted by 5-hydroxyalkyl